Published in Hepatitis Weekly, May 22nd, 2006
"HCV infection is an important cause of chronic liver disease. Standard therapy, pegylated interferon a (pegIFN alpha) combined with ribavirin, results in a sustained response rate in approximately half of patients," wrote F.H.T. Duong and colleagues, University of Basel Hospital.
They continued, "The cause of treatment failure in the other half of the patients is unknown, but viral interference with IFN alpha signal transduction through the Jak-STAT pathway might be an important factor."
"We have shown...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.